Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term FPF1100NW (selegiline) monotherapy in early Parkinson's disease
jRCT2080221954Phase 2
- Sponsor
- FP Pharmaceutical Corporation
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selegiline in Parkinson's disease (PD), sponsored by FP Pharmaceutical Corporation.
02
Drugs
selegiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2080221954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221954.